Maxime Dely: Helping Patients Live More Freely with Sickle Cell Disease
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”Sickle cell disease: an invisible illness with very real consequences
Often invisible from the outside, sickle cell disease remains one of the most common genetic disorders in France, affecting around 30.000 people. Behind this apparent invisibility lies a chronic condition that can deeply impact daily life.
This disease is caused by a genetic abnormality of hemoglobin, leading to the deformation of some red blood cells. Less flexible, these cells struggle to circulate through small blood vessels, causing pain crises, chronic anemia, and sometimes severe organ complications.
Treatment options are diverse: symptomatic care, prevention of complications, transfusions, and today, the development of gene therapies offering real hope for curative treatment.
Among the most effective approaches, red blood exchange by apheresis makes it possible to remove altered red blood cells and replace them with healthy donor red blood cells. This technique reduces blood viscosity, limits iron overload, and helps space out treatment sessions.
Beyond every protocol, there is one simple goal: helping patients live more freely.”
Other posts featuring Maxime Dely on Hemostasis Today.
-
Aug 22, 2026, 15:53Howard Smith: Publix’s GreenWise Organic Frozen Berries Have E. coli Contamination
-
Aug 22, 2026, 15:13Arthur Allen: Empowering Clinicians to Act
-
Aug 22, 2026, 15:11Bassem M. Mohammed: Factor VIII Structure Analysis Makes the Cover of the Journal of Thrombosis and Haemostasis
-
Aug 22, 2026, 15:03Ahmed Reda: Your Red Blood Cell Can Tell a Story – Not All Anemia Looks the Same
-
Aug 22, 2026, 14:50Marco Meloni: Clinical Management of the Diabetic Foot Attack
-
Aug 22, 2026, 14:41Nico Gagelmann: What is the Future for Patients with Myeloproliferative Neoplasms?
-
Aug 22, 2026, 14:36Arun V J: Leadership Is a Practice, Not a Position – TRAM Masterclass with Judith Chapman
-
Aug 22, 2026, 13:38Jerome Hadjadj: A New Approach to Refractory Immune Thrombocytopenia
-
Aug 22, 2026, 13:25Christopher Robinson: Hematologic Response to Iron Therapy and Stillbirth Risk